New drug hope for kids with MS: ublituximab trial launches
NCT ID NCT07220252
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This study tests the drug ublituximab in children aged 10 to 18 with relapsing multiple sclerosis (MS). It compares ublituximab to another drug, fingolimod, to see which better controls relapses. The trial involves 240 participants and will also monitor long-term safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ublituximab (a drug given by IV infusion)
- What this could lead to
- If successful, this could provide a new treatment option for children with relapsing multiple sclerosis to reduce relapses.
- What could go wrong
- This is an early-to-mid stage trial (Phase 2/3) with 240 participants, so results may not confirm long-term benefit or safety. Risks include infusion reactions and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
TG Therapeutics Investigational Trial Site
RECRUITINGGdansk, 80-952, Poland
-
TG Therapeutics Investigational Trial Site
NOT_YET_RECRUITINGPoznan, 60-355, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.